Table 2.
Clinical outcomes of the cohort overall and grouped by mHSPC treatment regimen (N = 106).
| Treatment received | Total (%) | De novo metastatic disease (%) | High-volume (CHAARTED)(%) | Undetectable PSA (%) | CRPC (%) | Median time to CRPC, months, (95%CI) |
|---|---|---|---|---|---|---|
| Overall | 106 (100) | 66 (62.3) | 68 (64.2) | 42 (39.6) | 57 (53.8) | 25.4 (20.3-30.4) |
| # Unknown | 0 (0) | 2 (1.9) | 13 (12.3) | 4 (3.8) | ||
| ADT ± first-generation anti-androgen | 29 (27.4) | 12 (41.4) | 15 (51.7) | 7 (24.1) | 18 (62.1) | 46.3 (18.9-73.7) |
| Treatment Intensificationa | 77 (72.6) | 54 (70.1) | 53 (68.8) | 35 (45.5) | 39(50.6) | 23.4 (18.6-28.2) |
| |ADT plus chemotherapyb | 21 (19.8) | 16 (76.2) | 18 (85.7) | 4 (19.0) | 17 (81.0) | 16.2 (12.3-20.1) |
| |Novel hormonal therapy | 48 (45.3) | 15 (31.3) | 29 (60.4) | 27(56.3) | 18 (37.5) | 26.6 (16.8-36.4) |
| ADT plus abiraterone acetate | 40 (37.7) | 27 (67.5) | 25 (62.5) | 24 (60.0) | 17 (42.5) | 28.1 (17.1-39.0) |
| ADT plus enzalutamide | 5 (4.7) | 3 (60.0) | 1 (20.0) | 3 (60.0) | 1 (20.0) | 22.6 (3.1-42.1) |
| ADT plus apalutamide | 3 (2.8) | 3 (100) | 3 (100) | 0 (0) | 0 (0) | — |
| |ADT plus chemotherapy plus NHTc | 8 (7.5) | 5 (62.5) | 6 (75.0) | 4 (50.0) | 4 (50.0) | 17.8 (10.3-25.3) |
aIncludes ADT plus chemotherapy and/or novel hormonal therapy.
bIncludes: N = 20 docetaxel, N = 1 carboplatin plus etoposide.
cIncludes: N = 6 ADT + enzalutamide + docetaxel, N = 2 ADT + abiraterone acetate + docetaxel.
Abbreviations: ADT, androgen deprivation therapy; CRPC, castrate resistant prostate cancer.